GSK downsizes in consumer healthcare consolidation

Share this article:
GlaxoSmithKline is laying off employees of its Consumer Healthcare unit as it moves its weight control and smoking cessation groups from Moon, PA, to Parsippany, NJ, The Pittsburgh Post-Gazette reported.

The layoffs, of an as-yet undetermined number, have already claimed nine directors, the paper reported, and come as the company is merging its smoking cessation and weight loss franchises into a single “behavioral sciences” unit based in Parsippany.

GSK Consumer Healthcare has around 1,200 US employees, including 500 at its Moon headquarters, 400 in Parsippany and 300 in field sales. Brands include Alli, the OTC weight loss drug, and NicoDerm, Nicorette and Commit for smoking cessation, along with Tums antacids and Aquafresh toothpaste.

Elsewhere in downsizing news, Pharmalot reported Monday that Boehringer Ingelheim is shedding around 200 US neurosciences sales reps following disappointing results on a large study of Aggrenox, which the sales team details for strokes, and the loss of a patent challenge on RLS drug Mirapex.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...